Eshelman Ventures, LLC — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Incyclix Bioincyclixbio.comin 𝕏Aug 2025

Incyclix Bio is a clinical-stage biotech company developing cell cycle control therapies that target the aberrant cell proliferation driving cancers, with a lead CDK2 inhibitor (INX-315).

BiotechHealthtechDurham, US

Patrick Roberts(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)

BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)

PartnerFred Eshelman· solo GP

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.